Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Mar 19, 2022 9:50am
90 Views
Post# 34527653

RE:RE:Quarterly Results on the 24th ...

RE:RE:Quarterly Results on the 24th ...
Chianchin wrote: Lula will be the next president of Brazil based on polls. Good luck with him GUD. Read https://www.britannica.com/biography/Luiz-Inacio-Lula-da-Silva


I don't think it's going to matter who's running Brazil Chi-Chi.
Just like you worried about Biogen's AD drug making it hard for GUD's EXELON in the future - none of that matters.  There are many tactics that can be used by GUD if they run into trouble.

Just pay attention to the numbers at the Q4 and 2021 full year results this Thursday.  That's likely what matters.

We'll be doing a head to head comparison with Paladin's 2003 full year numbers to see if we are ahead or behind in the long game ...

Why do we compare with Paladin?
Aferall - this is what drives Goodman - his personal goal is to beat Paladin.
That's why It's important - it's the measuring stick being used for GUD.



(7+ years into company development)

Paladin full year 2003 (for comparison with GUD full year 2021 when available)
-----------------------------

Revenue of $23,859,000
Income before write-downs of $2,511,000
Net income of -4,172,000
Earnings per share of -0.28
Cashflow of 5,444,000
Cash and Marketable Securities of 44,547,000
Shareholder Equity of 59,332,000
Shares Issued and Outstanding 14,799,588

Back in 2003, the message to shareholders was ... "Paladin Labs confronted significant challenges in 2003 and emerged as a stronger company."

- faced increased generic competition
- acquired 5 innovative marketed products and 2 late-stage development products

They knew how to right the ship - and - we have the same team but with much more experience this time around.  Let's see where they stand 7+ years in a head-to-head.

: )
<< Previous
Bullboard Posts
Next >>